|1.||Miyazawa, Teruo: 7 articles (03/2015 - 12/2002)|
|2.||Nakagawa, Kiyotaka: 5 articles (03/2015 - 12/2002)|
|3.||Matsuno, S: 4 articles (01/2001 - 01/2000)|
|4.||Kato, Shunji: 3 articles (03/2015 - 12/2011)|
|5.||Oikawa, Shinichi: 3 articles (02/2015 - 01/2005)|
|6.||Unno, M: 3 articles (01/2001 - 07/2000)|
|7.||Kakita, T: 3 articles (01/2001 - 07/2000)|
|8.||Takeuchi, H: 3 articles (01/2001 - 07/2000)|
|9.||Suzuki, M: 3 articles (01/2001 - 07/2000)|
|10.||Suzuki, Yuuri: 2 articles (03/2015 - 02/2015)|
01/01/2001 - "Using pig models, we designed two continuous ischemia groups, prepared by blockage of the blood flow at the hepatic hilum for 10 or 30 min. A discontinuous ischemia model was prepared by repeating the 10-min ischemia procedure, followed by 10 min of reperfusion, to a total ischemia period of 30 min. The PCOOH level started to increase just after reperfusion and reached the peak at 90 min, followed by a gradual decline after 6 h. "
05/01/1994 - "These results indicate that the occurrence of SPHOOH and LPCOOH, as well as PCOOH, may reflect liver damage related to ischemia-reperfusion."
05/01/1994 - "We detected the occurrence of PCOOH in both liver and plasma from rats subjected to hepatic ischemia-reperfusion, and demonstrated that liver and plasma PCOOH levels reflect the extent of liver injury. "
02/01/1994 - "Hepatic ischemia-reperfusion induced significant elevation of plasma PCOOH and caused liver injury in rats. "
11/17/1993 - "During periods of reperfusion following 30 min of ischemia, plasma PCOOH increased biphasically (2 nmol/mL; 12-24 hr duration of reperfusion), and generally ran parallel to that in the liver after more than 60 min of reperfusion. "
12/01/2011 - "The present study implies an important role of PCOOH in atherosclerosis progression and plaque instability."
02/01/1996 - "The present study also showed that AsA-deficiency especially invites an increase in plasma PCOOH together with a hyperlipidemic state which are risk factors in developing atherogenesis."
06/01/2000 - "Our results suggest that an increase in plasma PCOOH in patients with hyperlipidemia may be related to the development and progression of atherosclerosis, particularly in the elderly. "
03/20/2015 - "These results will enhance our fundamental understanding of how PCOOH, which is present in oxidized low density lipoproteins, is involved in the development of atherosclerosis. "
05/01/2009 - "These results indicate that PCOOH evokes LFA-1-mediated cell adhesion to ICAM-1 via actin cytoskeletal organization, and the mechanism may participate in monocyte adherence to the arterial wall in the initiation of atherosclerosis."
|4.||Chronic Kidney Failure (Chronic Renal Failure)
11/01/1995 - "Plasma PCOOH levels were significantly elevated in both DM patients, while the plasma PCOOH in normal controls were 227.0 +/- 68.7 pmol/ml. Plasma PCOOH levels of DM patients undergoing HD were significantly higher than that of patients without ESRD (1,330.8 +/- 642.7 pmol/ml vs. 756.6 +/- 431.9 pmol/ml, p < 0.025). "
05/01/2002 - "In patients with chronic renal failure, no difference in plasma pentosidine levels was observed between diabetic nephropathy and chronic glomerulonephritis, while a significant correlation was observed with phosphatidylcholine hydroperoxide, suggesting the possibility that the plasma pentosidine level reflects injury due to oxidation. "
12/01/2000 - "In this study, we employed a specific lipid peroxidative product, phosphatidylcholine hydroperoxide (PCOOH), and evaluated the peroxidative effect of end stage renal disease by measuring thiobarbituric acid reactive substances (TBARS) and PCOOH in both plasma and erythrocyte membrane. "
|4.||Hyaluronic Acid (Hyaluronan)
|5.||Thiobarbituric Acid Reactive Substances
|10.||Benzoic Acid (Ucephan)
|1.||Renal Dialysis (Hemodialysis)